Who are Lonsurf's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trifluridine and Tipiracil, Dendrid, Copegus (ribavirin), Peginterferon alfa-2a + ribavirin, Experimental: Valacyclovir treatment, intravenous (IV) ganciclovir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tipiracil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Lonsurf — Competitive Intelligence Brief

Lonsurf (TIPIRACIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside Analog Antiviral [EPC]. Area: Oncology.

marketed Nucleoside Analog Antiviral [EPC] Thymidine phosphorylase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lonsurf (TIPIRACIL) — Taiho Oncology Inc. Lonsurf works by inhibiting the enzyme thymidine phosphorylase, which is involved in the breakdown of certain cancer medications.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lonsurf TARGET	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01
Trifluridine and Tipiracil	Trifluridine and Tipiracil	Amgen	marketed	Antimetabolite combination; thymidylate synthase inhibitor	Thymidylate synthase; thymidine phosphorylase
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
Copegus (ribavirin)	Copegus (ribavirin)	Hoffmann-La Roche	marketed	Nucleoside analog antiviral	Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)
Peginterferon alfa-2a + ribavirin	Peginterferon alfa-2a + ribavirin	Hospital Clinico Universitario San Cecilio	marketed	Interferon alpha + nucleoside analog antiviral combination	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Experimental: Valacyclovir treatment	Experimental: Valacyclovir treatment	University of Pittsburgh	marketed	Nucleoside analog antiviral	Herpesvirus DNA polymerase
intravenous (IV) ganciclovir	intravenous (IV) ganciclovir	University of Oslo School of Pharmacy	marketed	Nucleoside analog antiviral	Viral DNA polymerase (CMV and herpes simplex virus)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-09-22 — Lonsurf · RE46284 · US
2034-06-17 — Lonsurf · 10457666 · US
2034-06-17 — Lonsurf · 9527833 · US
2034-09-05 — Lonsurf · 9943537 · US
2037-02-03 — Lonsurf · 10456399 · US
2037-02-03 — Lonsurf · 10960004 · US

Sponsor landscape (Nucleoside Analog Antiviral [EPC] class)

Taiho Oncology Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lonsurf — Competitive Intelligence Brief. https://druglandscape.com/ci/tipiracil. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab